Issue 19 | June 2019

catabasis CONNECTION

Updates on edasalonexent and clinical trials

PolarisDMD continues to move forward

Enrollment of the Phase 3 PolarisDMD trial of edasalonexent (edasa) in Duchenne is making strong progress! We believe that the vast majority of patients have been identified and screening activities are ongoing. PolarisDMD is enrolling approximately 125 boys, ages 4-7 (up to 8th birthday), who have not been on steroids for the past 6 months. PolarisDMD is a one-year placebo-controlled trial. Upon completion of the study, all boys may be eligible to receive edasalonexent in our open-label extension study, called GalaxyDMD. If you have questions about the trial, please reach out to **DMDtrials@catabasis.com**



TIPS FOR SWALLOWING CAPSULES FROM THE DUCHENNE COMMUNITY

In PolarisDMD, the study drug comes in gel capsules like the ones shown here and are taken 3 times a day with food. Since boys may find it tricky learning how to swallow capsules, we're passing on a few recently-received tips from families. Thanks to everyone for their advice!

First, practice swallowing with a small piece of candy like a Tic-Tac®, jelly bean, or M&M® and as your child masters that, you can graduate to candy that's closer in size to the capsule.

Take the capsules with something thick and sweet tasting, like jam or even a milkshake!

Try a MediStraw! Drop the capsule down the straw and he can drink it with a liquid he likes!

Have your child tilt his head back and then put the capsule at the very back of his tongue.

Above all, positivity and encouragement really help! Learning something new can take practice, but our experience has been that overall the boys do very well swallowing the study drug capsules.

ABOUT EDASALONEXENT

Edasalonexent inhibits NF-kB, a protein that plays a fundamental role in skeletal and cardiac muscle disease in Duchenne. By inhibiting NF-kB, edasalonexent has the potential to decrease inflammation and fibrosis, promote muscle regeneration, and slow disease progression. Edasa is being developed as a potential stand-alone therapy and may also have the potential to be combined with dystrophin-targeted therapies.

MAKING COMMUNITY CONNECTIONS



Cure Rare Disease—Catabasis will be attending the Cure Rare Disease "Power in Community Conference" on July 21st in Boston, MA. For more information, please visit **www.cureraredisease.org/events/**

Jett Foundation Family Workshops—Catabasis will attend the workshop in Chicago, IL on July 13th. Learn all about Jett Foundation's national education program at **www.jettfoundation.org/familyworkshops**

Parent Project Muscular Dystrophy—Catabasis will be attending PPMD's 25th Annual Conference on June 26th through 30th in Orlando, FL. To learn more about the event, please visit **www.parentprojectmd.org/get-involved/attend-events/annual-conference**

MDA Summer Camp—Catabasis will be attending MDA's Summer Camp on August 7th in Amston, CT, a life-changing day of fun and games, friendship and awesome adventures. Each summer thousands of kids attend across the U.S. at no cost to their families. For more information, please see: **www.mda.org/summer-camp**

Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy 2019—Catabasis will be presenting at the Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy, which is being held in conjunction with the International Conference on Children's Bone Health on June 21st in Salzburg, Austria. Catabasis will share information on the potential benefits of edasalonexent on muscle and bone health in Duchenne.

Stay in touch!

Join our mailing list: http://www.catabasis.com/patients-families/for-further-information.php

Follow us @CatabasisPharma.

Ask a question about the trial: DMDtrials@catabasis.com

The information provided here is for parents and caregivers of boys with Duchenne muscular dystrophy. Edasalonexent is an investigational drug that is not yet approved in any territory.

catabasis

POLARIS DMD